T Eisen

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi request reprint The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression
    T Eisen
    Eukaryotic Transcription Laboratory, Marie Curie Research Institute, Oxted, Surrey, UK
    Oncogene 11:2157-64. 1995
  2. pmc Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
    J S Waters
    Royal Marsden Hospital, London and Sutton, UK
    Br J Cancer 91:1763-8. 2004
  3. pmc Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
    T Eisen
    Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
    Br J Cancer 95:581-6. 2006
  4. ncbi request reprint The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
    E Andreopoulou
    Lung Unit, Royal Marsden Hospital, Surrey, UK
    Ann Oncol 15:1406-12. 2004
  5. pmc Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
    M J Allen
    Royal Marsden Hospital, London, UK
    Br J Cancer 83:980-5. 2000
  6. ncbi request reprint Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study
    M E R O'Brien
    Royal Marsden Hospital and Kent Cancer Centre, Sutton, Surrey, UK
    Ann Oncol 15:921-7. 2004
  7. ncbi request reprint TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
    A Matakidou
    Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
    Mutagenesis 18:377-85. 2003
  8. pmc Systematic review of the relationship between family history and lung cancer risk
    A Matakidou
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 93:825-33. 2005
  9. pmc Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
    T Eisen
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 82:812-7. 2000
  10. doi request reprint Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer
    S A Sohaib
    Department of Imaging, Royal Marsden Hospital, London, UK
    Br J Radiol 82:632-9. 2009

Collaborators

Detail Information

Publications21

  1. ncbi request reprint The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression
    T Eisen
    Eukaryotic Transcription Laboratory, Marie Curie Research Institute, Oxted, Surrey, UK
    Oncogene 11:2157-64. 1995
    ..The potential role of Brn-2/N-Oct3 in melanocyte differentiation and gene expression is discussed...
  2. pmc Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
    J S Waters
    Royal Marsden Hospital, London and Sutton, UK
    Br J Cancer 91:1763-8. 2004
    ..This combination of gemcitabine and capecitabine has modest activity in immunotherapy-refractory metastatic renal carcinoma with manageable toxicity...
  3. pmc Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
    T Eisen
    Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
    Br J Cancer 95:581-6. 2006
    ..i.d.). Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies...
  4. ncbi request reprint The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
    E Andreopoulou
    Lung Unit, Royal Marsden Hospital, Surrey, UK
    Ann Oncol 15:1406-12. 2004
    ..We have analysed prospectively collected data to evaluate a frequently used palliative chemotherapy regimen...
  5. pmc Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
    M J Allen
    Royal Marsden Hospital, London, UK
    Br J Cancer 83:980-5. 2000
    ..It is of particular interest that this regimen appears to have high activity in fit patients with poor prognostic features...
  6. ncbi request reprint Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study
    M E R O'Brien
    Royal Marsden Hospital and Kent Cancer Centre, Sutton, Surrey, UK
    Ann Oncol 15:921-7. 2004
    ..Vinorelbine and carboplatin are both active agents in the treatment of non-small-cell lung cancer (NSCLC). Vinorelbine has recently been developed in an oral formulation, which is as active as the intravenous (i.v.) form...
  7. ncbi request reprint TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
    A Matakidou
    Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
    Mutagenesis 18:377-85. 2003
    ..Additional well-designed studies based on sample sizes commensurate with the detection of small genotypic risks may allow a more definitive conclusion...
  8. pmc Systematic review of the relationship between family history and lung cancer risk
    A Matakidou
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 93:825-33. 2005
    ..The limitations of the currently published epidemiological studies to infer genetic susceptibility are discussed...
  9. pmc Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
    T Eisen
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 82:812-7. 2000
    ..No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted...
  10. doi request reprint Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer
    S A Sohaib
    Department of Imaging, Royal Marsden Hospital, London, UK
    Br J Radiol 82:632-9. 2009
    ..Whole-body MRI is a more sensitive method for detection of bone metastases in renal cancer than bone scintigraphy, and also allows the assessment of soft-tissue disease...
  11. pmc Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
    P J Ross
    Lung Unit, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK
    Br J Cancer 90:1905-11. 2004
    ..03, RR=1.92) and an independent predictor of progression-free survival in patients with SCLC (P=0.01, RR=1.43). In conclusion, weight loss as a symptom of lung cancer predicts for toxicity from treatment and shorter survival...
  12. pmc Survival from lung cancer in England and Wales up to 2001
    Y K Zee
    Department of Oncology, University of Cambridge, Box 193 Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, Cambridge, UK
    Br J Cancer 99:S43-6. 2008
  13. pmc Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis
    A Matakidou
    Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
    Br J Cancer 96:1904-7. 2007
    ....
  14. doi request reprint Prognostic factors for renal cell carcinoma
    D Furniss
    YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, United Kingdom
    Cancer Treat Rev 34:407-26. 2008
    ..Prospective validation of such integrated prognostic models will be essential...
  15. doi request reprint Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  16. pmc Prognostic significance of folate metabolism polymorphisms for lung cancer
    A Matakidou
    Section of Cancer Genetics, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 97:247-52. 2007
    ..36; 1.06-1.75). While there is evidence that variation in the folate metabolism genes may influence prognosis from lung cancer, current data are insufficiently robust to distinguish individual patient outcome...
  17. ncbi request reprint Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation
    U Khalid
    Division of Medicine, Imperial College London, Fulham Road, London, SW10 9NH, UK
    Support Care Cancer 15:39-46. 2007
    ..The effectiveness of treatment is impaired in patients with weight loss. The aetiology of this weight loss is complex and poorly characterised. Decreased calorie intake may be important. The reasons for decreased intake are unknown...
  18. ncbi request reprint Patient selection for palliative whole-brain radiotherapy based on RTOG recursive partitioning analysis
    K Harrington
    Clin Oncol (R Coll Radiol) 17:128. 2005
  19. ncbi request reprint Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century
    N W Yii
    Head and Neck Unit, The Royal Marsden NHS Trust, London, UK
    Clin Oncol (R Coll Radiol) 15:199-204. 2003
    ..Adding radiotherapy to surgery in tumours that could be radically excised did not confer any statistically significant advantage in reducing local recurrence or improving survival...
  20. pmc The treatment of advanced renal cell cancer with high-dose oral thalidomide
    J Stebbing
    Department of Medical Oncology, The Royal Marsden Hospital, London SW3 6JJ, UK
    Br J Cancer 85:953-8. 2001
    ..Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400 mg in currently accruing studies...